Logo image of QGEN

QIAGEN N.V. (QGEN) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:QGEN - NL0015002SN0 - Common Stock

52.38 USD
+4.81 (+10.11%)
Last: 1/20/2026, 11:40:09 AM
Fundamental Rating

6

QGEN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. QGEN gets an excellent profitability rating and is at the same time showing great financial health properties. QGEN has a correct valuation and a medium growth rate. These ratings would make QGEN suitable for quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year QGEN was profitable.
  • In the past year QGEN had a positive cash flow from operations.
  • Each year in the past 5 years QGEN has been profitable.
  • QGEN had a positive operating cash flow in each of the past 5 years.
QGEN Yearly Net Income VS EBIT VS OCF VS FCFQGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • QGEN's Return On Assets of 6.19% is amongst the best of the industry. QGEN outperforms 82.46% of its industry peers.
  • QGEN has a Return On Equity of 11.11%. This is amongst the best in the industry. QGEN outperforms 82.46% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.44%, QGEN is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
  • QGEN had an Average Return On Invested Capital over the past 3 years of 7.25%. This is significantly below the industry average of 13.75%.
  • The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(7.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.19%
ROE 11.11%
ROIC 7.44%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
QGEN Yearly ROA, ROE, ROICQGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15

1.3 Margins

  • The Profit Margin of QGEN (19.58%) is better than 94.74% of its industry peers.
  • QGEN's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 27.02%, QGEN belongs to the best of the industry, outperforming 96.49% of the companies in the same industry.
  • In the last couple of years the Operating Margin of QGEN has grown nicely.
  • Looking at the Gross Margin, with a value of 64.10%, QGEN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
  • In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
Industry RankSector Rank
OM 27.02%
PM (TTM) 19.58%
GM 64.1%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
QGEN Yearly Profit, Operating, Gross MarginsQGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so QGEN is destroying value.
  • Compared to 1 year ago, QGEN has less shares outstanding
  • The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
  • Compared to 1 year ago, QGEN has an improved debt to assets ratio.
QGEN Yearly Shares OutstandingQGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
QGEN Yearly Total Debt VS Total AssetsQGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 3.58 indicates that QGEN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of QGEN (3.58) is better than 68.42% of its industry peers.
  • QGEN has a debt to FCF ratio of 4.50. This is a neutral value as QGEN would need 4.50 years to pay back of all of its debts.
  • The Debt to FCF ratio of QGEN (4.50) is better than 73.68% of its industry peers.
  • QGEN has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.45, QGEN is doing worse than 63.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 4.5
Altman-Z 3.58
ROIC/WACC0.9
WACC8.27%
QGEN Yearly LT Debt VS Equity VS FCFQGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

  • QGEN has a Current Ratio of 2.60. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
  • QGEN's Current ratio of 2.60 is in line compared to the rest of the industry. QGEN outperforms 49.12% of its industry peers.
  • A Quick Ratio of 2.30 indicates that QGEN has no problem at all paying its short term obligations.
  • QGEN has a Quick ratio (2.30) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.3
QGEN Yearly Current Assets VS Current LiabilitesQGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

  • QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.41%, which is quite good.
  • The Earnings Per Share has been growing slightly by 7.92% on average over the past years.
  • The Revenue has been growing slightly by 5.32% in the past year.
  • Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)12.41%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%9.52%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.41% on average over the next years. This is quite good.
  • Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.12% on average per year.
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue Next Year5%
Revenue Next 2Y5.47%
Revenue Next 3Y5.71%
Revenue Next 5Y7.12%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QGEN Yearly Revenue VS EstimatesQGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
QGEN Yearly EPS VS EstimatesQGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

  • QGEN is valuated rather expensively with a Price/Earnings ratio of 21.29.
  • QGEN's Price/Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 92.98% of the companies in the same industry.
  • QGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 20.21, QGEN is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of QGEN to the average of the S&P500 Index (24.29), we can say QGEN is valued inline with the index average.
Industry RankSector Rank
PE 21.29
Fwd PE 20.21
QGEN Price Earnings VS Forward Price EarningsQGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 85.96% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 24.04
EV/EBITDA 13.9
QGEN Per share dataQGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • QGEN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.74
PEG (5Y)2.69
EPS Next 2Y7.68%
EPS Next 3Y8.33%

2

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.54%, QGEN is not a good candidate for dividend investing.
  • QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.09. QGEN pays more dividend than 96.49% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, QGEN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.54%

5.2 History

  • QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
QGEN Yearly Dividends per shareQGEN Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2Y7.68%
EPS Next 3Y8.33%
QGEN Yearly Income VS Free CF VS DividendQGEN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

QIAGEN N.V.

NYSE:QGEN (1/20/2026, 11:40:09 AM)

52.38

+4.81 (+10.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04
Earnings (Next)02-03
Inst Owners85.46%
Inst Owner Change-0.4%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap11.36B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts72.5
Price Target54.17 (3.42%)
Short Float %N/A
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield 0.54%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)4.85%
PT rev (3m)3.41%
EPS NQ rev (1m)5.26%
EPS NQ rev (3m)3.23%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.24%
Valuation
Industry RankSector Rank
PE 21.29
Fwd PE 20.21
P/S 5.48
P/FCF 24.04
P/OCF 17.27
P/B 3.11
P/tB 14.24
EV/EBITDA 13.9
EPS(TTM)2.46
EY4.7%
EPS(NY)2.59
Fwd EY4.95%
FCF(TTM)2.18
FCFY4.16%
OCF(TTM)3.03
OCFY5.79%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.74
PEG (5Y)2.69
Graham Number30.52
Profitability
Industry RankSector Rank
ROA 6.19%
ROE 11.11%
ROCE 10.03%
ROIC 7.44%
ROICexc 10.67%
ROICexgc 39.98%
OM 27.02%
PM (TTM) 19.58%
GM 64.1%
FCFM 22.82%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 4.5
Debt/EBITDA 2.17
Cap/Depr 97.52%
Cap/Sales 8.94%
Interest Coverage 250
Cash Conversion 87.76%
Profit Quality 116.56%
Current Ratio 2.6
Quick Ratio 2.3
Altman-Z 3.58
F-Score8
WACC8.27%
ROIC/WACC0.9
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.41%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%9.52%
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year5%
Revenue Next 2Y5.47%
Revenue Next 3Y5.71%
Revenue Next 5Y7.12%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.16%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%

QIAGEN N.V. / QGEN FAQ

Can you provide the ChartMill fundamental rating for QIAGEN N.V.?

ChartMill assigns a fundamental rating of 6 / 10 to QGEN.


Can you provide the valuation status for QIAGEN N.V.?

ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.


What is the profitability of QGEN stock?

QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.


What is the earnings growth outlook for QIAGEN N.V.?

The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 7.77% in the next year.